Loading...
Plasma proteome alterations by MAPK inhibitors in BRAF(V600)-mutated metastatic cutaneous melanoma()()
Approximately half of metastatic cutaneous melanomas (CM) harbor a mutation in the BRAF protooncogene, upregulating the mitogen-activated protein kinase (MAPK)-pathway. The development of inhibitors targeting the MAPK pathway (MAPKi), i.e., BRAF- and MEK-inhibitors (BRAFi and MEKi), have substantial...
Saved in:
| Published in: | Neoplasia |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Neoplasia Press
2021
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8274243/ https://ncbi.nlm.nih.gov/pubmed/34246984 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2021.06.002 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|